Brief: New Meta-Analysis Demonstrates That Access To The Genesight Test Can Significantly Improve Response And Remission Rates For Patients With Depression
03/09/2025 22:51
Myriad Genetics Inc MYGN.O: NEW META-ANALYSIS DEMONSTRATES THAT ACCESS TO THE GENESIGHT TEST CAN SIGNIFICANTLY IMPROVE RESPONSE AND REMISSION RATES FOR PATIENTS WITH DEPRESSION Source text: ID:nGNX8jVkqZ Further company coverage: MYGN.O
Recent news on Myriad Genetics
See all newsUS STOCKS ON THE MOVE-Hilton, MSCI, Tradeweb, Eli Lilly
US STOCKS ON THE MOVE-Hilton, MSCI, Tradeweb, Eli Lilly
Myriad jumps after agreeing to sell prenatal health testing business
Brief: Myriad Genetics To Sell Prenatal Health Testing Business To Labcorp
U.S. STOCKS ON THE MOVE- Medtronic, Comstock, Apple